[14] In patients with diabetes, overly aggressive glycemic control or inadequate adjustment of concurrent diabetes medications (particularly insulin or sulfonylureas) may result in hypoglycemia or relative hypoglycemia, even if glucose values remain within normal range
BMI 30 or higher strong chance of coverage BMI 27+ with a weight-related condition may qualify with a supporting diagnosis Employer plan rules coverage limits and approved medications vary Prior authorization required WeightWatchers helps you navigate the paperwork Insurance can bring your monthly medication cost down to as little as $0$100/month
High Expenditure and Supply Chain Issues: Major Limitations In the global GLP-1 receptor agonist market, arising challenges are the high expenses of these drugs, which pose a hurdle for many patients
[1] Clinical trial data from the SURPASS programme indicates that these reactions occur in a small percentage of patients receiving tirzepatide
Beans and lentils are also a decent source of protein
The remaining trials (TRIUMPH-2/-3/-4 and TRIUMPH-Outcomes) are still anticipated through 20262028